Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...

Simple external cues, such as lines on the floor, can help Parkinson’s patients focus their efforts and overcome the ...

Parkinson’s disease is a progressive neurological disorder in which ongoing changes in the brain affect and interfere with ...

A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...

Researchers at the Foundation have uncovered new insights into the complex link between dopamine and rest tremor in Parkinson ...

The new Ochsner site will contribute to uncovering additional genes as well as examine health disparities and care access for ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...